A number of strategies, including both local and systemic immunosuppression, are currently used to increase the success rate of high-risk corneal transplants. In the large majority of corneal transplant recipients, corticosteroids are still the gold standard for prevention and treatment of rejection. When rejection risk is considered to be high, single and combined administration of stronger immunosuppressive drugs such as tacrolimus, cyclosporine and mycophenolate mofetil (MMF) are often prescribed to reduce the likelihood of transplant failure. However, the prolonged use of these medications can cause significant side effects and increase the risk of infection. For this reason, new or alternative treatments are badly needed to safely prevent rejection of high-risk corneal transplants and/or to reduce potential adverse side effects of currently prescribed immunosuppressive drugs.
- New VISICORT publication in Kidney360 journalJanuary 28, 2021 - 11:47 am
- Trio of VISICORT PIs will present at 2021 CDx Biomarkers and Biobanking BioTec Pharma SummitJanuary 15, 2021 - 10:29 am
- VISICORT consortium meets on November 27, 2020December 10, 2020 - 12:31 pm
- Corneal Transplant Follow-up Study II (CTFS II) – Does tissue matching reduce the risk of rejection in corneal transplants?December 7, 2020 - 3:11 pm
- VISICORT receives a 6-month extensionNovember 6, 2020 - 5:06 pm
- Exploitation news: A collaboration with Epimune GmbH beginsAugust 18, 2020 - 11:13 am
- 2020 COP&S conference coordinated by VISICORT PI Dr Bertrand Fabres slated for November 12 & 13thAugust 17, 2020 - 3:36 pm
- VISICORT presented at Ophthalmology changing event, BerlinAugust 17, 2020 - 1:37 pm
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602470. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.